iData Insights

Ischemia Reperfusion Injury - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 25, 2016 12:09 IST

Ischemia Reperfusion Injury - Pipeline Review, H2 2015 Summary Global Markets Direct s, Ischemia Reperfusion Injury - Pipeline Review, H2 2015, provides an overview of the Ischemia Reperfusion Injurys therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ischemia Reperfusion Injury and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ischemia Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ischemia Reperfusion Injury pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173365/ischemia-reperfusion-injury-pipeline-review-h2-2015

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=173365/ischemia-reperfusion-injury-pipeline-review-h2-2015

Table of Contents

Introduction 7

Global Markets Direct Report Coverage 7

Ischemia Reperfusion Injury Overview 8

Therapeutics Development 9

Pipeline Products for Ischemia Reperfusion Injury - Overview 9

Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis 10

Ischemia Reperfusion Injury - Therapeutics under Development by Companies 11

Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes 14

Ischemia Reperfusion Injury - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Ischemia Reperfusion Injury - Products under Development by Companies 19

Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes 21

Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 23

Alligator Bioscience AB 23

Angion Biomedica Corp. 24

Antipodean Pharmaceuticals, Inc. 25

Biomedica Management Corporation 26

Bolder Biotechnology, Inc. 27

Curatis Pharma GmbH 28

Enteris BioPharma, Inc. 29

Erimos Pharmaceuticals, LLC (Inactive) 30

Gilead Sciences, Inc. 31

Ischemix 32

Kowa Company, Ltd. 33

LG Life Science LTD. 34

Omeros Corporation 35

Opsona Therapeutics Limited 36

Peptinnovate Limited 37

Pharming Group N.V. 38

PledPharma AB 39

Prolong Pharmaceuticals 40

Proteo, Inc. (Inactive) 41

Prothix BV 42

Trophos SA 43

Zealand Pharma A/S 44

Ischemia Reperfusion Injury - Therapeutics Assessment 45

Assessment by Monotherapy Products 45

Assessment by Target 46

Assessment by Mechanism of Action 49

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

ADC-1004 - Drug Profile 56

AM/AMBP-1 - Drug Profile 57

Annexin A-1 - Drug Profile 60

ANV-6L15 - Drug Profile 61

APP-103 - Drug Profile 62

BB-3 - Drug Profile 63

BBT-059 - Drug Profile 66

C1 esterase inhibitor (human) - Drug Profile 67

CMX-2043 - Drug Profile 72

CRX-526 - Drug Profile 74

Curaglutide - Drug Profile 75

danegaptide - Drug Profile 76

Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drug Profile 78

EP-80317 - Drug Profile 79

GS-459679 - Drug Profile 80

KN-93 - Drug Profile 81

mangafodipir trisodium - Drug Profile 83

MG-53 - Drug Profile 84

mirococept - Drug Profile 86

MitoQ - Drug Profile 88

Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile 90

Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - Drug Profile 91

Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile 93

MTP-131 - Drug Profile 94

NBD Peptide - Drug Profile 96

NecX - Drug Profile 98

Neutrolide - Drug Profile 99

NP-202 - Drug Profile 101

Oligonucleotide for Oncology and Cardiovascular - Drug Profile 103

OMS-721 - Drug Profile 104

OPN-305 - Drug Profile 106

PAC-G31P - Drug Profile 108

PIN-201601 - Drug Profile 110

pitavastatin NP - Drug Profile 111

PRO-02 - Drug Profile 112

R-190 - Drug Profile 113

Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile 115

Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury - Drug Profile 116

Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile 117

Recombinant Proteins for Ischemia Reperfusion Injury - Drug Profile 118

Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 119

Recombinat Protein to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile 120

Sanguinate - Drug Profile 121

Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 123

Small Molecules for Ischemia Reperfusion Injury - Drug Profile 124

Small Molecules for Ischemia Reperfusion Injury - Drug Profile 125

Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile 126

Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile 127

Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 128

SMTP-7 - Drug Profile 129

Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile 130

Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile 131

terameprocol - Drug Profile 132

tiprelestat - Drug Profile 134

TRO-40303 - Drug Profile 137

UCF-101 - Drug Profile 139

UWA-TAT - Drug Profile 140

Ischemia Reperfusion Injury - Recent Pipeline Updates 141

Ischemia Reperfusion Injury - Dormant Projects 160

Ischemia Reperfusion Injury - Discontinued Products 164

Ischemia Reperfusion Injury - Product Development Milestones 165

Featured News & Press Releases 165

Appendix 173

Methodology 173

Coverage 173

Secondary Research 173

Primary Research 173

Expert Panel Validation 173

Contact Us 173

Disclaimer 174"

Read More http://www.idatainsights.com/reports-landing-page.php?id=173365/ischemia-reperfusion-injury-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects